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Sickle Cell Disease Treatment: 
Important Information for 
Patients and Health Care Providers
Sickle cell disease (SCD) is a group of genetic blood disorders that can cause complications ranging from 
mild, to serious, and even deadly. But many people with SCD are living longer, healthier lives than in the past 
because more is known about how to prevent and treat dangerous complications. This booklet is designed to 
help SCD patients and families, together with their health care providers, make informed decisions about their 
care. Please talk to your primary care doctor or hematologist about any questions or concerns you have.
Introduction
SCD is group of genetic disorders in which abnormal hemoglobin causes problems with the red blood 
cells that carry oxygen throughout the body. Normal red blood cells are round, flexible, and slippery and 
flow easily through small blood vessels. The red blood cells of persons with SCD become quarter-moon 
or crescent shaped, sticky and rigid when they give up oxygen in the small blood vessels. Sickle red blood 
cells do not live as long (15-30 days) as normal red blood cells (120 days). This shorter life span of the red 
cells causes anemia or low hemoglobin level, which may cause tiredness, shortness of breath or decreased 
energy. The sickled cells can also block the flow of blood in various parts of the body causing pain, 
infection, acute chest syndrome (severe pneumonia), stroke and major damage to organs. Other health 
problems include difficulty breathing, jaundice, and delayed growth and development in children.
SCD is found throughout the world. It is most common in people whose ancestors come from Africa, 
Mediterranean countries (such as Turkey, Greece, and Italy), the Middle East, India, Central and South 
America and the Caribbean. In the United States approximately 100,000 people have SCD and it is most 
common in African Americans and Hispanics. There are four common types of sickle cell disease with 
somewhat different clinical problems and family histories. Sickle cell anemia (Hb SS) and sickle beta zero 
thalassemia (Hb S βo Thal) tend to have more problems and hemoglobin SC disease (Hb SC) and sickle 
beta plus thalassemia (Hb S β+ Thal) are somewhat milder in childhood. 
People with SCD in the United States are living longer, healthier lives because of advances in treatment 
and prevention of complications. These include: 
1. Life-threatening infections in infants and children can be prevented through newborn screening for 
the disease, family education, immunizations, and use of penicillin.
2. Serious complications of infection can be avoided through early treatment and good general health 
care.
3. People at high risk for stroke due to SCD can be identified through trans-cranial Doppler ultrasound 
screening tests and given treatments to reduce their risk of having a stroke.
4. Use of hydroxyurea drug treatment can reduce the severity of anemia, reduce episodes of pain and 
acute chest syndrome, and increase longevity for people with SCD. 
This booklet is designed to help SCD patients and families, together with their health care providers, make informed decisions 
about their care. Please talk to your primary care doctor or hematologist about any questions or concerns you have.
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Prevention of Life-Threatening Infections with Immunization & 
Penicillin
Immunizations
Infections are the major cause of death in infants and young children with 
SCD, with children under five years of age at highest risk. One key way 
to prevent infections is through immunizations, which help the body to 
build natural defenses against bacteria and viruses. Children with SCD 
should receive all the routine immunizations recommended for all children. 
Recommended schedules for these routine immunizations change from 
year to year but are updated annually by the CDC and the American 
Academy of Pediatrics, and are well known to most primary care providers. 
Because infections with pneumococcal and meningococcal bacteria are 
especially dangerous, additional immunizations for these two infections 
are also recommended for children with SCD beginning at age two years. 
The pneumococcal polysaccharide vaccine (PPV) is given at 2 years and 
repeated five years later.  The meningococcal conjugate vaccine is also given 
at 2 years and repeated 2 months later. Parents should keep their child’s 
immunization record, and insist they receive their immunizations on schedule.
Prophylactic Penicillin
Additionally, the daily administration of oral penicillin has been shown to reduce the incidence of severe 
pneumococcal infection in children with SCD under five years of age. A leading study published in 1986 
found that children treated with penicillin had an 84% reduction in the incidence of life-threatening infection, 
compared with those not taking penicillin. This study concluded that children should be screened through 
a newborn screening program for hemoglobin disorders, and those with SCD should receive prophylactic 
therapy with oral penicillin by 2 months of age in order to decrease morbidity and mortality from pneumococcal 
septicemia. Thus, Immunizations, and daily penicillin reduce the chance that fatal infections will occur. 
However because they do not provide protection against all life-threatening infections, it also is important that 
parents watch their children carefully for signs of infection, and seek urgent medical care for fever. 
Prevention of Stroke with Trans-Cranial Doppler (TCD) Ultrasound 
Screening & Transfusions
Trans-Cranial Doppler
Children with Hb SS and Hb S β0Thal are 300 times more likely than other children to have a stroke. These 
strokes are caused by damage to large arteries in the brain which eventually leads to blockage of blood flow 
or bleeding in the brain. Strokes can permanently affect one’s ability to move his or her arms and legs, speak, 
remember, and learn. Once a child with SCD has had a stroke, their chance of having a second stroke is about 
80%, unless they undergo regular blood transfusions. Strokes can also cause death. 
Trans-Cranial Doppler (TCD) is a test that uses ultrasound (sound waves) to measure the speed of blood flow 
in the main blood vessels of the brain to determine whether a child with Hb SS or Hb S β0Thal is at high risk 
for having a stroke. Regularly scheduled blood transfusions can then be used to prevent a first stroke. Children 
with Hb SS and Hb S β0Thal should begin having annual TCD screening tests at age two years until age 
sixteen or more often dependent upon the findings. TCD screening is unnecessary and not recommended for 
children with Hb SC and Hb S β+ Thal. 
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Chronic Transfusions
Treatment with regularly scheduled (usually monthly) blood transfusions can prevent stroke by replacing 
abnormal sickle blood cells with normal red blood cells. Therefore, chronic transfusions are usually 
recommended for children who have had a stroke or are identified as being at high risk for stroke through 
abnormal TCDs, It should be noted, however, that while transfusion therapy can be very effective in preventing 
strokes, transfusions can cause a number of complications. The following are risks associated with transfusion 
therapy:
• Hemolytic and allergic reactions to transfusions.
• Development of antibodies against transfused red cells that can cause potentially severe transfusion 
reactions and may make it harder to find the best units for transfusions in blood banks.
• Iron overload that can damage the liver, heart and other organs.  To prevent this organ damage, patients 
who receive many transfusions need to take a drug to remove the excess iron. 
• Transfusion associated infections.
Hydroxyurea
Hydroxyurea, a chemotherapeutic (cancer treatment) drug, has been shown to reduce episodes of pain and 
acute chest syndrome, reduce anemia and need for transfusion, and improve the quality of life in children and 
adults with Hb SS and Hb S β0Thal.  There is presently no data to show it benefits individuals with Hb SC and 
Hb S β+ Thal. There is now evidence from around the World that individuals with Hb SS and Hb S β0Thal who 
are taking hydroxyurea are living longer than those who are not on the drug.
Fetal hemoglobin is the hemoglobin that we all have before we are born, and in persons with SCD, it blocks 
the sickling of the red blood cells. After birth, the production of fetal hemoglobin decreases, and this benefit 
is reduced. Hydroxyurea was first tested on SCD in 1984 and has been shown to increase fetal hemoglobin 
levels in persons with SCD, making the red blood cells less likely to sickle. Hydroxyurea also reduces the white 
blood cells, platelets, and stickiness of red blood cells that may also be of benefit. Therefore SCD patients on 
hydroxyurea may experience less of the painful episodes, acute chest syndrome, anemia, stroke, and other 
health problems associated with SCD. 
Benefits
There is still much to be learned about hydroxyurea therapy for SCD patients, but its noted benefits include: 
• Decreased frequency of pain episodes
• Less pain and feeling healthier
• Reduced anemia
• Prevention of acute chest syndrome (ACS)
• Decreased need for hospitalization
• Prolonged life.
Potential Side Effects
Hydroxyurea is taken orally and most individuals 
taking the drug have no side effects and feel 
better than before they started the drug. The most 
common reported side effect of hydroxyurea is mild 
nausea or upset stomach; though most patients 
have this only for the first few weeks, and taking 
the medicine at bedtime can reduce these effects. 
Hydroxyurea also slows production of red blood 
cells, white blood cells and platelets. The anemia 
improves because the red blood cells last longer in 
the blood. Too much reduction in red cell production 
by hydroxyurea could lead to more severe anemia. 
Mild suppression of the white blood cells and 
platelets may also be of benefit but severe reduction 
can lead to infection and bleeding. Because of this, 
hydroxyurea dosing needs to be carefully adjusted 
and blood cell counts monitored every two to four weeks to make sure that the suppression does not become 
severe.  If the blood counts become too low, the hydroxyurea is usually given in a lower dose or stopped for a 
few weeks and restarted at a lower dose.
Less common side effects of hydroxyurea include allergic reactions, thinning hair, darkening skin or nails, and, 
rarely, changes in liver or kidney function. These are usually reversible when the drug is stopped. Because 
this is chemotherapy, there was concern that long-term use could increase the risk of cancer or leukemia. 
There is no evidence that this is true in individuals with sickle cell disease. It is important that males or females 
not conceive a child while they are on hydroxyurea in order to avoid the possibility of having a child with birth 
defects. It is recommended that all individuals on hydroxyurea abstain from sex or use highly effective methods 
of birth control. So far, the babies born to mothers on hydroxyurea for SCD have not had birth defects. 
However, it is recommended that hydroxyurea be stopped for at least six weeks before conceiving a baby to 
avoid this possibility. Another possible effect among men taking hydroxyurea is decreased sperm counts or 
sperm movement, which may be temporary and reversible.
Some people have worried that hydroxyurea treatment will slow the growth or development of children with 
SCD. So far, studies of hundreds of children over a few years have not revealed growth and development 
problems, and newer evidence suggests that hydroxyurea may help reduce or delay the neurocognitive defects 
associated with SCD. 
Bottom Line
Hydroxyurea therapy for a child or adult with sickle cell disease has many possible benefits, several known 
risks, and potential long-term side effects. All of the benefits and risks will not be known until more research on 
hydroxyurea treatment is done in sickle cell and large numbers of patients are followed for years on the drug. 
Most physicians knowledgeable about sickle cell disease presently recommend that most individuals with Hb 
SS and Hb S β0Thal consider using hydroxyurea. We strongly recommend individual discussions of the risks 
and benefits of hydroxyurea with a physician knowledgeable about use of hydroxyurea in SCD to help decide 
whether you or your child should take the drug.
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Find Out More
Resources and Support:
• Sickle Cell Foundation of Georgia, Inc.: 404-755-1641; toll-free 800-326-5287; sicklecellga.org
• Sickle Cell Information Center: scinfo.org
• CDC Information: www.cdc.gov/ncbddd/sicklecell
Comprehensive sickle cell centers:
• Children’s Healthcare of Atlanta: 404-785-1200
• Georgia Regents University: 706-721-2171
• Grady Health System: 404-616-3572
Newborn Screening Program:
• Georgia Department of Public Health: 404-657-4143; health.state.ga.us/programs/nsmscd
For more information and resources, visit: http://ghpc.gsu.edu/project/hemoglobin-disorders-data-
coordinating-center/
A 2014 NIH Expert Panel Report includes evidence-based guidelines that recommended increased adoption of 
hydroxyurea in the care of individuals with SCD. 
Update: See the 11/19/2014 media advisory from NIH on new, positive findings regarding hydroxyurea use 
with TCD to reduce stroke risk.
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